• Skip to main navigation
  • Skip to main content
  • Skip to Footer
  • Navigate Novartis
    • Patients
    • Healthcare Professionals
    • Media
    • Investors
    • Partners
    • ESG
    • Job Seekers
    • Clinical Trials
  • Coronavirus
  • Global
    • Novartis site directory
Novartis logo: a global healthcare company
  • Our Company
    • Our Leadership
      • Board of Directors
      • Executive Committee of Novartis
    • Our Approach
      • Strategy
      • Corporate Responsibility
      • Diversity & Inclusion
      • Partnering
      • People and Culture
    • Our Business
      • Global Product Portfolio
      • Innovative Medicines
      • Novartis Pharmaceuticals
      • Novartis Gene Therapies
      • Novartis Oncology
      • Sandoz
    • Media
      • Newsroom
      • News Archive
      • Multimedia Resources
      • Subscribe to Updates
    • Investors
      • Event Calendar
      • Financial Data
      • Share Data & Analysis
      • Shareholder Information
      • Environmental, Social & Governance
  • Our Focus
    • Disease Areas
      • Cancer
      • Cardiovascular, Renal and Metabolic Medicine
      • Immunology & Dermatology
      • Ophthalmology
      • Neuroscience
      • Respiratory
    • Platforms and Technology
      • Data and Digital
      • Cell & Gene Therapy
    • Novartis Stories
      • Discovery
      • From Our Labs
      • Access to Healthcare
      • Patient Perspectives
      • People and Culture
      • Live Magazine
  • Our Impact
    • Building Trust with Society
      • Corporate Responsibility
      • Ethical Standards
      • Access
      • Environmental Sustainability
    • Global Health
      • Malaria
      • Sickle Cell Disease
      • Chagas disease
      • Leprosy
      • Novartis Foundation
    • ESG Performance and Reporting
      • Materiality Assessment
      • Environmental, Social and Governance
      • Transparency and Disclosures
      • Positions on Key Topics
      • Statements on Key Issues
  • Our Science
    • Research & Early Development
      • Novartis Institutes for BioMedical Research
      • Research Disease Areas
      • Postdoc Program
      • Open Source Science
    • Drug Development at Novartis
      • Novartis Pipeline
      • Clinical Trials
      • Translational Medicine
      • Global Product Portfolio
    • Science Stories
      • Discovery
      • From Our Labs
  • Careers
    • Your Career
      • Global Career Search
      • Teams and Skills
      • Gene Therapies Careers
    • Working at Novartis
      • Diversity & Inclusion
      • People and Culture
      • Corporate Responsibility
    • Career Programs
      • Our Career Programs
      • Students and Scholars
      • Novartis Quantitative Sciences Hackathon
Search
Partnerships aim to improve cancer care around the world.
  • TwitterTweet
  • FacebookShare
  • Share
    • Twitter
    • Facebook
    • LinkedIn
    • Email
    • Whatsapp
  • Jump to Comments
Stories/Access to Healthcare

Partnering for improved cancer care around the globe

Novartis works tirelessly with third-party organizations to improve access to cancer care.

Feb 02, 2018

“A medicine is only as good as the system that delivers it,” said Dr. Harald Nusser, Head of Novartis Social Business, when Novartis joined forces with the American Society for Clinical Pathology and the American Cancer Society in 2017 to fight cancer, including breast cancer, in Africa. 

Approximately 650 000 people develop cancer annually in Africa, and about 510 000 cancer deaths happen each year as a consequence of lack of access to treatment, as of 20151. The challenge of access to quality cancer care in Africa is complex and involves multiple factors beyond the treatment itself. For instance, in Ethiopia, which has a population of more than 100 million people, there are currently less than 10 oncologists. Other challenges relate to medical equipment, training of healthcare workers, and disease stigma, according to Dr. Wondimagegn Tigineh, head of the Department of Radiation Oncology at Black Lion Hospital in Addis Ababa, Ethiopia (Watch the video). 

The programs established by this partnership in Ethiopia, Rwanda, Tanzania and Uganda aim to provide patients with rapid cancer diagnostics as well as appropriate care and treatment – crucial pillars to help countries address cancer care. 

Funded by Novartis, work on the ground will include building healthcare capacity for immunohistochemistry analysis in six hospital laboratories in Ethiopia, Rwanda, Tanzania and Uganda. Further, training of healthcare professionals will also be organized to ensure quality processes in the transportation of biopsy samples and the administration of chemotherapy. 

In some parts of the world, the infrastructure needs to be built first. In others, the infrastructure exists and yet there are still roadblocks to receiving treatment.

In some parts of the world, the infrastructure first needs to be created before being able to provide the necessary treatment. In others, the infrastructure exists and yet there are still roadblocks to receiving care - as was the case for patients with chronic myeloid leukemia (CML). To help ensure these patients receive the treatment they need, Novartis and The Max Foundation took an existing access program and created a new, independent, patient-centered model. Called CMLPath to CareTM, this humanitarian access-to-treatment system evolved from a program established in 2002. CMLPath to CareTM is based on the insights gained from working with people in specific countries’ healthcare systems to address the challenges of delivering care to individual patients. Novartis provides funding and drug donation support, while The Max Foundation delivers treatment to patients, psychological support and manages all aspects of supply chain management.

Together with our partners, we aim to connect more patients to the care they need.
Appropriate care and treatment are both crucial pillars to help countries address cancer care.

 

This global healthcare partnership with The Max Foundation is part of the long-term focus of Novartis to help bring CML care to those in need. This groundbreaking initiative is one of the broadest cancer programs led by a patient-centered nongovernmental organization (NGO); treatment and support are provided to patients at no cost and the program is implemented in nearly 70 countries worldwide. 

As we continue to work to develop therapies for life-threatening diseases, we will also strive to ensure our treatments are accessible to those who need it most. Together with our partners, we are working tirelessly to connect patients to care, resources and each other. Collaborations like these are essential to improve cancer care around the globe.

Health educator Chankey Kumar addresses people in the northern Indian village of Mulehra
Access to Healthcare

Pioneering business approach expands healthcare in Indian villages

 

Shareline

Novartis partnerships aim to improve global access to healthcare and #cancer treatment.
Tweet Tweetpopo

Novartis Access

Novartis has a long-term commitment to collaborate with health authorities, NGOs and other third parties who share a common goal of improving access to healthcare and medicines.

Learn more about how we improve access to healthcare in lower-income countries

Tags: 
Access to Healthcare, Africa, Global Health Partnerships, Novartis Social Business, Oncology
Disclaimer: 

References:
1. ASCP. White House Announces Global Initiative to Accelerate Fight Against Cancer in Africa. October 2015. http://labculture.ascp.org/community/news/2015/10/29/white-house-announces-global-initiative-to-accelerate-fight-against-cancer-in-africa

    • TwitterTweet
    • FacebookShare
    • Share
      • Twitter
      • Facebook
      • LinkedIn
      • Email
      • Whatsapp
    • Jump to Comments
  • Print
  • Save

Novartis Stories

View all

Dr. Theophile Tuyisabe standing next to his patients smiling at him
Access to Healthcare

Meet a visionary who beat the odds to realize his vision of inclusive eye care

Access to Healthcare

Chagas disease: Breaking the silence

Sandoz in Kalwe, India ensures multidrug therapy (MTD) supply to WHO to fight leprosy
Access to Healthcare

Ensuring medicine supply to patients during COVID-19

You are here

  1. Home ›
  2. Stories ›
  3. Access healthcare

Novartis Global

  • Navigate Novartis

    • Patients & Caregivers
    • Healthcare Professionals
    • Investors
    • Media
    • Society & ESG
    • Partners
  • Contact Us

    • Global Contacts
    • Office Locations
    • For Investors
    • For Media
  • About Novartis

    • Our Company
    • Our Focus
    • Our Impact
    • Our Science
    • Our Stories
  • Our Portfolio

    • Global Product Portfolio
    • Global Clinical Pipeline
  • Careers

    • Career Search

Connect with Novartis

  • twitter
  • linkedin
  • youtube
  • facebook
  • instagram
Novartis Site Directory
© 2021 Novartis AG
  • Terms of Use
  • Privacy Policy
  • Contact Us
  • Site Map
  • Cookie Settings

This site is intended for a global audience.